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OBJECTIVES The study evaluated the transcardiac extraction or spillover of aldosterone (ALDO) in normal
subjects and in patients with congestive heart failure (CHF).
BACKGROUND Aldosterone promotes collagen synthesis and structural remodeling of target organs such as
the heart. Spironolactone, an ALDO receptor antagonist, has recently been reported to
reduce the mortality of patients with CHF; however, the effects of spironolactone on the
transcardiac gradient of ALDO have not been clarified.
METHODS We measured plasma ALDO in the aortic root (AO) and coronary sinus (CS) in normal
subjects and 113 consecutive CHF patients and also measured plasma procollagen type III
aminoterminal peptide (PIIINP) in CS, a biochemical marker of myocardial fibrosis.
RESULTS Plasma ALDO was significantly lower in the CS than in the AO in normal subjects (n 5 15;
61.2 6 9.3 vs. 83.1 6 11.8 pg/ml, p , 0.0001). In 96 CHF patients who did not receive
spironolactone, plasma ALDO was significantly lower in the CS than in the AO (59.3 6 3.9 vs.
73.8 6 4.9 pg/ml, p , 0.0001). In contrast to the difference in these 96 patients, there was no
significant difference in ALDO between the AO and CS in 17 patients who received
spironolactone (127.4 6 20 vs. 124.0 6 19 pg/ml, p 5 0.50). Stepwise multivariate analyses
showed that spironolactone therapy had an independent and significant negative relationship with
the transcardiac gradient of plasma ALDO in patients with CHF. In addition, significant positive
correlations were seen between the transcardiac gradient of plasma ALDO and PIIINP (r 5
0.565, p , 0.0001) and the left ventricular end-diastolic volume index (r 5 0.484, p , 0.0001).
CONCLUSIONS These results indicate that plasma ALDO is extracted through the heart in normal subjects
and in CHF patients who do not receive spironolactone and that spironolactone inhibits the
transcardiac extraction of ALDO in CHF patients, suggesting that spironolactone blocks the
effects of ALDO on the failing heart in patients with CHF. (J Am Coll Cardiol 2000;36:
838–44) © 2000 by the American College of Cardiology
Despite the outstanding success of angiotensin-converting
enzyme (ACE) inhibitors in the treatment of congestive heart
failure (CHF), the mortality rate of CHF patients remains
higher than that of normal subjects. This high mortality rate is
partly due to the aldosterone escape phenomenon in patients
who received ACE inhibitors (1–4). Moreover, the plasma
angiotensin II (Ang II) level is not constantly decreased during
long-term treatment with ACE inhibitors (5), partly because
Ang II may be produced by alternative pathways (6). There-
fore, angiotensin type 1 receptor antagonists or aldosterone
(ALDO) receptor antagonists such as spironolactone may have
additional advantages over ACE inhibitors (3,7). Recently,
spironolactone was shown to reduce the mortality of CHF
patients who had already received ACE inhibitors, digitalis,
and diuretics. In the Randomized Aldactone Evaluation Study
(RALES) (3,8), both sudden death and CHF death were
significantly reduced with spironolactone. However, despite
the great impact of the RALES results, the mechanism of the
improvement of mortality with spironolactone remains to be
fully elucidated.
Aldosterone displays both myocardial and renal effects that
may have profound implications for left ventricular remodeling
(9). Significant associations were found between plasma
ALDO and left ventricular mass in patients with hypertension
as well as in a population-based sample, suggesting that
aldosterone may be an important factor in the modulation of
cardiac structure (10–12). Recently, it has been reported that
mineralocorticoid receptor, which mediates the action of
ALDO, is expressed in cardiomyocytes, endothelial cells, and
fibroblasts in the human heart (13–15). Aldosterone, secreted
from the adrenal gland, has been shown to stimulate cardiac
collagen synthesis and fibroblast proliferation via activation of
local mineralocorticoid receptors or via an unexplained indirect
mechanism (16–19). However, the relationship between the
cardiac effect of ALDO and the mechanism of cardiac fibrosis
by ALDO has not been fully elucidated. More recently, cardiac
production of ALDO has been reported in rats (20), suggest-
ing the possibility of cardiac production of ALDO in humans.
However, a transcardiac gradient of ALDO in humans has not
been demonstrated.
In the present study, we measured plasma levels of
ALDO both in the aortic root and the coronary sinus, and
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we evaluated whether ALDO is extracted or spilled over
through the heart in normal subjects and in patients with
CHF. Moreover, we also evaluated the effects of spirono-
lactone on the transcardiac gradient of ALDO and deter-
mined the relationship between the transcardiac gradient of
ALDO and the left ventricular remodeling.
METHODS
Patients. The subjects were 113 consecutive patients with
symptomatic left ventricular dysfunction (left ventricular ejec-
tion fraction [LVEF] ,45%) without renal failure who un-
derwent cardiac catheterization for clinical indications. Patients
with angina pectoris, secondary hypertensive heart disease,
renal failure, or liver dysfunction were excluded. Patients with
coronary stenosis (.70%) were excluded. We also selected 15
age-matched normal subjects (age, 34 to 71; mean: 54 years)
who were admitted complaining of chest pain and whose
hearts proved to be normal by coronary angiography. Informed
consent was obtained from all patients before participation in
the study, and the protocol was approved by the Human
Investigations Committee of our institution.
The subjects were 75 men and 38 women ranging in age
from 17 to 79 years (mean: 58 years); 68 patients had suffered
a myocardial infarction more than three months before the
study, 38 had dilated cardiomyopathy, 5 had hypertensive heart
disease, and 2 had valvular heart disease. Sixty-eight patients
with old myocardial infarction had previously received percu-
taneous transluminal coronary angioplasty (PTCA) in our
hospital. Eighty-four patients were classified according to the
standards of the New York Heart Association (NYHA) as
functional class II, 25 patients as class III, and 4 patients as
class IV. At entry to the study, 76 patients were treated with
furosemide, 17 with spironolactone (a dose of 25 to 50 mg
daily), 79 with ACE inhibitors, 58 with digitalis, 37 with
vasodilators, and 27 with beta-blockers. Most drugs had been
administered for more than two months.
Study protocol. All patients were premedicated with an oral
dose of diazepam (5 mg) and rested in bed in the supine
position for at least 20 min. Right-sided cardiac catheterization
was performed using a 7F Swan-Ganz catheter. The heart rate
was monitored by electrocardiography. Blood samples for
measuring plasma ALDO were collected simultaneously from
the aortic root (AO) and coronary sinus (CS). A 6F catheter
(Goodman, Tokyo, Japan) for blood sampling was positioned
in the CS, and the position of the catheter was confirmed by
injection of contrast medium just after blood sampling. The
validity of CS blood sampling was also verified by simultaneous
measurements of the atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP) levels in the AO and CS. In 79 of
113 patients, blood samples for measuring the plasma levels of
procollagen type III aminoterminal peptide (PIIINP) were
drawn from the CS.
A Swan-Ganz catheter was inserted through the right
femoral vein into the main pulmonary artery, where the
pressure was measured. The catheter was then advanced
into the pulmonary artery, and the pulmonary capillary
wedge pressure was measured by inflating the balloon.
Cardiac output was determined by the thermodilution
method immediately after blood collection. Left ventricu-
lography was performed using contrast medium after the
hemodynamic measurements and blood sampling.
Measurement of neurohumoral factors. Blood for the
measurement of the plasma levels of ANP and BNP was
transferred to a chilled tube containing EDTA (1 mg/ml)
and aprotinin (500 kallikrein inactivator units/ml), and then
centrifuged at 3,000 rpm for 15 min at 4°C. The plasma
thus obtained was stored at 230°C until assayed. Plasma
concentrations of ANP and BNP were measured with a
specific immunoradiometric assay for using a commercial kit
(Shionogi, Osaka, Japan) as previously reported (21).
Blood for measurement of the plasma levels of ALDO
was transferred to a chilled tube containing EDTA
(1 mg/ml), centrifuged at 3,000 rpm for 15 min at 4°C, and
the plasma thus obtained was stored at 230°C until it was
assayed. Plasma ALDO levels were measured using a
commercial radioimmunoassay kit. This assay system for
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ALDO 5 aldosterone
Ang II 5 angiotensin II
ANP 5 atrial natriuretic peptide
AO 5 aortic root
BNP 5 brain natriuretic peptide
CHF 5 congestive heart failure
CS 5 coronary sinus
LVEDVI 5 left ventricular end-diastolic volume index
LVEF 5 left ventricular ejection fraction
PIIINP 5 procollagen type III aminoterminal peptide
Table 1. Hemodynamic and Neurohumoral Data
LVEF
(%)
MPAP
(mm Hg)
PCWP
(mm Hg)
LVEDP
(mm Hg)
LVEDVI
(l/min/m2)
ANP
(pg/ml)
BNP
(pg/ml)
ALDO in AO
(pg/ml)
ALDO in CS
(pg/ml)
Mild CHF (n 5 84) 35.6 16.9 8.7 11.3 122 71.7 87.5 73.6 61.2
(SE) (0.7) (0.4) (0.3) (0.5) (3.9) (11.3) (8.3) (5.6) (4.4)
Severe CHF (n 5 29) 22.9* 30.6* 20.7* 25.4* 196* 207* 459* 119.6* 102*
(SE) (1.8) (2.1) (1.8) (1.9) (12) (24) (72) (15) (14)
LVEF 5 left ventricular ejection fraction; MPAP 5 mean pulmonary arterial pressure; PCWP 5 pulmonary capillary wedge pressure; LVEDP 5 left ventricular end-diastolic
pressure; LVEDVI 5 left ventricular end-diastolic volume index; ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; ALDO 5 aldosterone; AO 5 ascending
aorta; CS 5 coronary sinus; SE 5 standard error.
*p , 0.0001 vs. mild CHF.
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plasma ALDO did not cross-react with angiotensin I or II,
spironolactone, ANP, or BNP. Plasma levels of PIIINP
were measured with a specific immunoradiometric assay
using a commercial kit (CIS Bio International, Nagoya,
Japan).
Statistical analysis. All results are expressed as the mean 6
SEM. Univariate analyses were performed using the Stu-
dent t test. To evaluate the contribution of ALDO to left
ventricular remodeling, univariate and stepwise multivariate
analyses were used among the 18 variables. Univariate and
Table 2. Univariate and Multivariate Linear Model of Left Ventricular End-Diastolic Volume
Index in 113 Patients With CHF
Variable
Univariate
Correlation
Coefficient
p
Value
Multivariate
Beta Coefficient
p
Value
Age (yr) 20.115 0.283
Gender (male 5 1; female 5 0) 20.223 0.0057
Etiology (ICM 5 1; non-ICM 5 0) 20.536 ,0.0001
NYHA functional class 0.473 ,0.0001
LVEF (%) 20.665 ,0.0001 23.4 ,0.0001
Mean blood pressure (mm Hg) 20.236 0.003
Cardiac index (l/min/m2) 20.029 0.758
Left ventricular end-diastolic pressure (mm Hg) 0.337 0.0003
Atrial natriuretic peptide (pg/ml) 0.487 ,0.0001
Brain natriuretic peptide (pg/ml) 0.351 0.0002
ALDO in AO (pg/ml) 0.317 0.0006
(AO-CS) ALDO (pg/ml) 0.484 ,0.0001 0.720 ,0.0001
Treatment (treatment 5 1; no treatment 5 0)
Spironolactone 0.302 0.005
Diuretics 0.473 ,0.0001
Digitalis 0.419 ,0.0001
ACE inhibitors 20.174 0.081
Vasodilators 20.290 0.006
Beta-blockers 0.117 0.128
ICM 5 ischemic cardiomyopathy; LVEF 5 left ventricular ejection fraction; ALDO 5 plasma aldosterone; AO 5 aortic root;
CS 5 coronary sinus; ACE 5 angiotensin-converting enzyme.
Table 3. Univariate and Multivariate Linear Model of Transcardiac Gradient of Plasma
Aldosterone in 113 Patients With CHF
Variable
Univariate
Correlation
Coefficient
p
Value
Multivariate
Beta Coefficient
p
Value
Age (yrs) 20.031 0.744
Gender (male 5 1; female 5 0) 20.067 0.438
Etiology (ICM 5 1, non-ICM 5 0) 20.109 0.251
NYHA functional class 0.280 0.0029
LVEF (%) 20.224 0.018
Mean blood pressure (mm Hg) 20.180 0.059
Cardiac index (l/min/m2) 20.097 0.309
Left ventricular end-diastolic blood pressure
(mm Hg)
0.250 0.008
Left ventricular end-diastolic volume index
(ml/m2)
0.484 ,0.0001 0.217 ,0.0001
Atrial natriuretic peptide (pg/ml) 0.370 ,0.0001
Brain natriuretic peptide (pg/ml) 0.231 0.389
ALDO (pg/ml) 0.371 ,0.0001 0.10 0.0052
Treatment (treatment 5 1;
no treatment 5 0)
Spironolactone 20.207 0.027 214.7 0.0115
Diuretics 0.114 0.228
Digitalis 0.056 0.554
ACE inhibitors 20.176 0.062
Vasodilators 20.089 0.348
Beta-blockers 20.062 0.512
ICM 5 ischemic cardiomyopathy; LVEF 5 left ventricular ejection fraction; ALDO 5 plasma aldosterone; AO 5 aortic root;
ACE 5 angiotensin-converting enzyme.
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stepwise multivariate linear regression analyses were also
used to detect independent predictors of the transcardiac
gradient of plasma ALDO among the 18 variables. Linear
regression analysis was used to determine the relationship
between continuous variables. A p value ,0.05 was re-
garded as significant.
RESULTS
Difference between plasma concentration of ALDO in
aortic root and coronary sinus. In the 15 age-matched
normal subjects, the plasma ALDO level was signifi-
cantly lower in the CS than in the AO (Fig. 1) (61.2 6
9.3 vs. 83.1 6 11.8 pg/ml, p , 0.0001). In 113 consecutive
CHF patients, plasma ALDO was also significantly lower in
the CS than in the AO (69.0 6 4.8 vs. 81.9 6 5.4 pg/ml, p ,
0.0001). In the 96 patients without spironolactone treatment,
plasma ALDO was significantly lower in the CS than in the
AO (Fig. 2) (59.3 6 3.9 vs. 73.8 6 4.9 pg/ml, p , 0.0001). In
contrast to the difference in the patients who did not receive
spironolactone, there was no significant difference of ALDO
between the AO and CS in the 17 patients who received
spironolactone (Fig. 2) (127.4 6 20 vs. 124.0 6 19 pg/ml, p 5
0.50). Plasma ALDO level was significantly higher in the
patients who received spironolactone than in the patients who
did not receive spironolactone.
Hemodynamic and neurohumoral data. Patients were
divided into two groups according to symptoms and were
analyzed for hemodynamic and neurohumoral data (Table
1). Hemodynamic parameters such as pulmonary capillary
wedge pressure, left ventricular end-diastolic pressure, and
left ventricular end-diastolic volume index (LVEDVI) were
significantly higher in severe CHF patients (NYHA class
III or class IV) than in mild CHF patients (NYHA class II).
The LVEF was significantly lower in severe CHF than in
mild CHF patients. Neurohumoral factors such as ANP,
BNP, and ALDO were significantly higher in severe CHF
patients than in mild CHF patients. Plasma ALDO was
significantly lower in the CS than in the AO in mild CHF
patients and in severe CHF patients.
Relationship between plasma ALDO extraction across
the heart and LVEDVI. Table 2 shows the results of
univariate and multivariate analyses to assess the factors
regulating the LVEDVI in 113 patients with CHF. Ac-
cording to stepwise multivariate analyses, only a high
transcardiac gradient of plasma ALDO (p , 0.0001) and
LVEF (p , 0.0001) were significant independent predictors
of a large LVEDVI. Figure 3 shows the correlation between
the LVEDVI and the plasma levels of ALDO in the AO
(r 5 0.317; p 5 0.0006) and the transcardiac gradient of
plasma ALDO (r 5 0.484; p , 0.0001) in patients with
CHF. A significant positive correlation existed between the
transcardiac extraction of plasma ALDO and plasma level
of PIIINP in the CS (Fig. 4; r 5 0.565; p , 0.0001), and
also a significant correlation between the plasma level of
PIIINP in the CS and LVEDVI (r 5 0.448; p , 0.0001).
Relationship between plasma ALDO in aortic root and
ALDO extraction across the heart. Table 3 shows the
results of univariate and multivariate analyses among 18
variables to assess the factors regulating the transcardiac
extraction of plasma ALDO. According to stepwise multi-
variate analyses, a high level of plasma ALDO in the AO
and treatment with spironolactone were significant inde-
pendent predictors of transcardiac extraction of plasma
ALDO in patients with CHF. Figure 5 shows a significant
correlation between the plasma level of ALDO in the AO
and the transcardiac extraction of plasma ALDO by linear
regression analysis in the 96 patients not treated with
spironolactone (r 5 0.759; p , 0.0001). There was no
correlation between the plasma level of ALDO in the AO
and the transcardiac extraction of plasma ALDO in 17
patients who received spironolactone, and most of the 17
patients who received spironolactone were on the right side
of the linear regression line of the 96 patients who did not
receive spironolactone (Fig. 5).
Figure 1. Plasma aldosterone (ALDO) concentrations in the aortic root
(AO) and coronary sinus (CS) in normal subjects.
Figure 2. Plasma aldosterone (ALDO) concentrations in the aortic root
(AO) and coronary sinus (CS) in patients with congestive heart failure
(CHF). Left panel shows data of ALDO in 96 CHF patients who did not
receive spironolactone; right panel shows data of ALDO in 17 CHF
patients who received spironolactone. *, p , 0.0001 vs. the value of AO.
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DISCUSSION
It has been recently reported that mineralocorticoid recep-
tors, which mediate the action of ALDO, are expressed in
the human heart (13–15). Cardiac fibrosis in rats induced by
ALDO infusion was not inhibited by concomitant admin-
istration of an ACE inhibitor or an Ang II receptor
antagonist, losartan, but was completely blocked by con-
comitant administration of the mineralocorticoid receptor
antagonist potassium canrenoate (22). However, the rela-
tionship between the cardiac effect of ALDO and the
mechanism of cardiac fibrosis by ALDO has not been fully
elucidated in vivo. We demonstrated here for the first time
that plasma ALDO is extracted through the heart in normal
subjects and in patients with CHF, and that a positive
correlation exists between the transcardiac gradient of
ALDO and LVEDVI. Moreover, spironolactone therapy
inhibited the ALDO extraction through the failing heart.
These findings indicate that the heart is a target organ of
ALDO, and that spironolactone, a mineralocorticoid recep-
tor antagonist, inhibits the ALDO extraction through the
heart in patients with CHF.
We also found a positive correlation between the trans-
cardiac ALDO extraction and the plasma level of PIIINP,
a possible biochemical marker of myocardial fibrosis (23,24)
in the CS, suggesting that the increase of the transcardiac
ALDO extraction in the failing heart stimulates myocardial
collagen turnover, as shown in vitro (19). Our finding of a
positive correlation between the transcardiac ALDO extrac-
tion and the plasma level of PIIINP also suggests that the
sustained transcardiac ALDO extraction is an important
modulator of left ventricular remodeling in the failing heart
regardless of the plasma ALDO levels. Klappacher et al.
(23) reported a significant positive correlation between
serum PIIINP and the amount of myocardial collagen type
III on cardiac biopsy in patients with CHF. Moreover, Host
et al. (24) showed that after a myocardial infarction, the
plasma level of PIIINP was higher in those patients with a
poor prognosis. Therefore, the plasma level of PIIINP may
be a biochemical marker of myocardial fibrosis and/or left
ventricular remodeling in patients with CHF. Indeed, in the
present study, there was a positive correlation between the
plasma level of PIIINP and LVEDVI. In addition, the
positive correlation between the transcardiac ALDO extrac-
tion and the plasma level of PIIINP suggests an interaction
between ALDO extraction and left ventricular remodeling
in patients with CHF.
Recently, spironolactone therapy has been reported to
cause a decrease in the level of PIIINP in patients with
CHF who have already received ACE inhibitors (25).
Therefore, taken together with our findings, the significant
reduction of mortality by spironolactone in CHF patients
(8) who have already received furosemides and ACE inhib-
itors may be partly due to the inhibition of transcardiac
ALDO extraction and to reduced collagen turnover in the
failing heart.
Study limitations. The transcardiac gradient of ALDO
was indirect evidence of ALDO receptors in the heart, and
the transcardiac extraction of circulating ALDO may not be
simply due to the existence of intracellular mineralocorticoid
receptors in the heart. Further studies are needed to evaluate
the mechanism of ALDO extraction, but our data may be
clinically important due to consistency with previous studies
that the heart is one of the important target organs of
ALDO. The small number of severe CHF patients (NYHA
class IV) was also a limitation of the present study. Treat-
ments, such as those using ACE inhibitors, beta-blockers
and spironolactone, were not randomized. Despite these
limitations of the effects of the present study, we can
conclude that spironolactone therapy is an independent
factor for reducing the transcardiac gradient of ALDO. We
measured the plasma transcardiac gradient of ALDO before
and after treatment with spironolactone in three patients
with CHF, which was decreased after spironolactone in all
three patients (data not shown). However, further studies
including serial measurements of ALDO in the AO and CS
and the left ventricular volume before and after treatment
with spironolactone are needed to confirm our hypothesis.
Figure 3. Correlation between left ventricular end-diastolic volume index (LVEDVI) and the plasma levels of aldosterone (ALDO) in the aortic root (AO)
and the transcardiac gradient of plasma ALDO in patients with congestive heart failure. AO 5 aortic root; CS 5 coronary sinus.
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Conclusions. In both normal subjects and CHF patients,
plasma ALDO was significantly lower in the CS than in the
AO, suggesting ALDO extraction across the heart. The
transcardiac gradient of plasma ALDO was independently
regulated by plasma ALDO in the AO and by spironolac-
tone therapy. Moreover, the transcardiac gradient of plasma
ALDO was correlated with LVEDVI and plasma level of
PIIINP, a marker of myocardial fibrosis in patients with
CHF. These findings suggest that elevated circulating
ALDO is extracted across the failing heart in CHF patients,
and that therapy for reducing plasma ALDO and/or
ALDO receptor antagonist would inhibit the process of left
ventricular remodeling in patients with CHF.
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